Phenibut-LF for the preparation of a solution for oral administration 250 mg in bags No. 10

DescriptionCrystallic powder of white or white color with a yellowish or grayish tint. Soft lumps are allowed. Composition Each package contains: active ingredient: phenibut – 250 mg; excipients: aspartame (E 951), mannitol (E 421), flavor additive “Lemon” (maltodextrin, gum arabic (E 414), aromatic products, aromatic substances, natural aromatic substances). Release form Powder for solution for oral administration. Pharmacotherapeutic group Other psychostimulants and nootropics. ATC code N06BX22 Pharmacological properties Pharmacodynamics The active substance of the drug Neurofen (γ-amino-β-phenylbutyric acid hydrochloride) can be considered as a derivative of γ-aminobutyric acid (GABA) or as a derivative of β-phenylethylamine. Neurofen has nootropic activity, and as a GABA derivative it has an anxiolytic (tranquilizing) effect. Does not affect cholinergic and adrenergic receptors. Does not have anticonvulsant activity. The drug lengthens the latent period of nystagmus and shortens its duration and severity. Pharmacokinetics The drug is well absorbed after oral administration and penetrates into all tissues of the body, penetrates the blood-brain barrier. About 0.1% of the administered dose of the drug penetrates into the brain tissue, and in young and old people to a much greater extent. 80-95% of the dose is metabolized in the liver to pharmacologically inactive metabolites. About 5% is excreted by the kidneys unchanged. With the repeated introduction of cumulation is not observed. Indications for use Apply with increased nervous excitability (neurasthenia) and sleep disorders. In children – for the treatment of stuttering, tics. Contraindications Hypersensitivity to the active substance or auxiliary components of the drug. Acute renal failure. Phenylketonuria, due to the presence of aspartame in the composition of the drug. During pregnancy and breastfeeding. Method of application and dosage Dissolve the contents of the package in half a glass of warm water and take it orally after meals. The prepared solution is not subject to storage, it should be taken immediately after preparation. The duration of the course of treatment is determined by the doctor, taking into account the disease, the tolerance of the drug and the effect achieved. With increased nervous excitability (neurasthenia) and sleep disorders. Inside after eating 2-3 week courses. Adults and children from 14 years of age are prescribed 250-500 mg 3 times a day (maximum daily dose of 1500 mg). Children from 8 to 14 years old – 250 mg 3 times a day. A single maximum dose in adults and children from 14 years old is 750 mg, in people over 60 years old – 500 mg, from 8 to 14 years old – 250 mg. Relief of alcohol withdrawal syndrome in the first days of treatment: during the day, 250-500 mg 3 times a day and at night 750 mg, with a gradual decrease in the daily dose to the usual for adults. Motion sickness prevention: 250-500 mg once 1 hour before the expected start of motion or when the first mild symptoms of motion sickness appear. The anti-swaying effect of phenibut increases with increasing dose of the drug. With the onset of pronounced manifestations of motion sickness (vomiting, etc.), the appointment of phenibut orally is ineffective even at doses of 750-1000 mg. Otogenic labyrinthitis and Meniere’s disease during an exacerbation: 750 mg 3-4 times a day for 5-7 days, with a decrease in the severity of vestibular disorders – 250-500 mg 3 times a day for 5-7 days and then – 250 mg 1 time per day for 5 days. For mild diseases – 250 mg 2 times a day for 5-7 days, followed by a dose reduction to 250 mg 1 time per day for 7-10 days. Asthenic conditions: inside, 40-80 mg / day, in some cases – up to 200-300 mg / day for 1-1.5 months. Depressive conditions of late age – 2-3 times a day, 40-200 mg / day for 1.5-3 months. Adverse reactionsEstimation of side effects is based on the following data on the frequency of occurrence: very often (≥1/10), often (≥1/100 to <1/10), infrequently (≥1/1000 to <1/100), rarely ( ≥1/10,000 to <1/1,000), very rare (<1/10,000), frequency unknown (cannot be estimated from available data). Nervous system disorders: unknown - drowsiness (at the beginning of treatment), increased irritability, agitation, anxiety, headache, dizziness (when taking phenibut in doses of more than 2000 mg (4 packets) per day, with a decrease in the dose, the severity of side effects decreases) . Gastrointestinal disorders: unknown - nausea (at the beginning of treatment). Skin and subcutaneous tissue disorders: rarely - allergic reactions (skin rash, itching). Liver and biliary tract disorders: unknown - hepatotoxicity (with prolonged use of high doses). There have been reports of cases of development of emotional instability and sleep disturbances in children after taking the drug. There are data on cases of tolerance (addiction) to the drug. In case of adverse reactions, including those not listed in the instructions for use, you should consult a doctor. Overdose No cases of overdose have been reported. In case of an overdose, the following symptoms may develop: drowsiness, nausea, vomiting, dizziness. With prolonged use of high doses, eosinophilia, arterial hypotension, impaired renal activity, and fatty degeneration of the liver (more than 7 g) may develop. Treatment: gastric lavage, symptomatic treatment. There is no specific antidote. Precautions Caution should be exercised in patients with erosive and ulcerative diseases of the gastrointestinal tract due to the irritant effect of the drug. These patients are prescribed smaller doses of the drug. With prolonged use, it is necessary to monitor peripheral blood and liver function. If the symptoms of the disease persist or worsen while taking the drug, you should consult a doctor. The composition of the drug includes aspartame, which is a source of phenylalanine and is contraindicated in patients with phenylketonuria. Do not use if the integrity of the package is violated. Pregnancy and breastfeeding Use during pregnancy and lactation is contraindicated, because. there are no adequate and well-controlled clinical studies on the safety of the drug during these periods. Influence on the ability to drive vehicles and work with mechanisms In connection with possible disorders of the central nervous system (drowsiness, dizziness), while taking the drug, you should not drive vehicles or service mechanisms. Interaction with other drugs Combining the drug with other psychotropic drugs requires prior consultation with a doctor and supervision of a doctor during treatment. The simultaneous administration of the drug with carbamazepine, oxcarbazepine or monoamine oxidase inhibitors is not recommended. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Packing 3 g of powder in a bag of combined material. Five, ten, fifteen, thirty packages along with instructions for medical use in a pack of cardboard. Shelf life 2 years. Do not use after the expiry date stated on the package. Buy Phenibut-LF for the preparation of an oral solution 250mg in bags No. 10